Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix

International Journal of Cancer

Volumn 139, Issue 5, 2016, Pages 1040-1045

  Castanon, Alejandra ^a   Landy, Rebecca ^a   Sasieni, Peter D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

adenocarcinoma; adenosquamous; cervical cancer; effectiveness of screening; screening

Indexed keywords

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; CANCER GRADING; CARCINOMA, ADENOSQUAMOUS; CASE CONTROL STUDY; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PATHOLOGY; PROCEDURES; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CASE-CONTROL STUDIES; CERVIX UTERI; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; UTERINE CERVICAL NEOPLASMS;

EID: 84974801101     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30152     Document Type: Article

References (32)

1. Mathew A, George PS., Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide. Asian Pac J Cancer Prev 2009; 10: 645-50.
2. Lonnberg S, Hansen BT, Haldorsen T, et al., Cervical cancer prevented by screening: long-term incidence trends by morphology in Norway. Int J Cancer 2015; 137: 1758-64.
3. Vinh-Hung V, Bourgain C, Vlastos G, et al., Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007; 7: 164
4. Adegoke O, Kulasingam S, Virnig B., Cervical cancer trends in the United States: a 35-year population-based analysis. J Women's Health (Larchmt) 2012; 21: 1031-7.
5. Sherman ME, Wang SS, Carreon J, et al., Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005; 103: 1258-64.
6. Visioli CB, Zappa M, Ciatto S, et al., Increasing trends of cervical adenocarcinoma incidence in Central Italy despite Extensive Screening Programme, 1985-2000. Cancer Detect Prev 2004; 28: 461-4.
7. Pettersson BF, Hellman K, Vaziri R, et al., Cervical cancer in the screening era: who fell victim in spite of successful screening programs? J Gynecol Oncol 2011; 22: 76-82.
8. Trent Cancer Registry, Profile of Cervical Cancer in England: incidence, mortality and survival, 2012.
9. IARC Working Group on the Evaluation of Cancer Preventative Strategies. Cervix cancer screening, ed., vol. 10. Lyon, France: IARC Press, 2005. 302 p.
10. Zappa M, Visioli CB, Ciatto S, et al., Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 2004; 90: 1784-6.
11. Mitchell H, Medley G, Gordon I, et al., Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer 1995; 71: 894
12. Mitchell H, Hocking J, Saville M., Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer Cytopathol 2003; 99: 336-41.
13. Pimenta JM, Galindo C, Jenkins D, et al., Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer 2013; 13: 553
14. Davy ML, Dodd TJ, Luke CG, et al., Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003; 101: 38-45.
15. Sasieni P, Castanon A, Cuzick J., Screening and adenocarcinoma of the cervix. Int J Cancer 2009; 125: 525-9.
16. Sasieni P, Castanon A., NHSCSP audit of invasive cervical cancer: national report 2009-2012, 2013.
17. Sasieni P, Adams J, Cuzick J., Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89: 88-93.
18. Sasieni P, Castanon A, Cuzick J., Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339:
19. NHS Cervical Screening Programme. Audit of Invasive Cervical Cancers. NHSCSP Publication 28, Sheffield, 2006.
20. Statacorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP., 2011.
21. Crocetti E, Battisti L, Betta A, et al., The cytological screening turned out effective also for adenocarcinoma: a population-based case-control study in Trento, Italy. Eur J Cancer Prev 2007; 16: 564-7.
22. Herbert A, Singh N, Smith JA., Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology 2001; 12: 26-36.
23. Pak SC, Martens M, Bekkers R, et al., Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol 2007; 47: 504-7.
24. Sasieni P, Castanon A, Cuzick J., Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339: b2968
25. Sankaranarayanan R, Nene BM, Shastri SS, et al., HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
26. Castellsague X, Diaz M, de Sanjose S, et al., Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303-15.
27. Nieminen P, Kallio M, Hakama M., The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995; 85: 1017-21.
28. Andrae B, Andersson TM, Lambert PC, et al., Screening and cervical cancer cure: population based cohort study. BMJ 2012; 344: e900
29. de Sanjose S, Quint WG, Alemany L, et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
30. Ronco G, Dillner J, Elfstrom KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-32.
31. Paavonen J, Naud P, Salmeron J, et al., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
32. Rodriguez-Carunchio L, Soveral I, Steenbergen RD, et al., HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG 2015; 122: 119-27.